Allergen News and Research

RSS

Australian research helps to better understand asthma, hayfever, eczema and associated allergies

May 4, 2004 is World Asthma Day. Asthma, hayfever, eczema and associated allergies are among the most common chronic diseases in the developed world. It has been estimated that up to 50% of people in western societies suffer from these conditions, and in Australia alone, health care costs for asthma alone exceed $700 million each year.

29 Apr 2004

Millions of poor and minority children in America's cities likely will suffer higher rates of asthma

Millions of poor and minority children in America's cities likely will suffer even higher rates of asthma as the result of a "powerful one-two punch" of higher levels of pollen and changes in the types of molds spurred by global warming, along with unhealthy urban air masses caused by the burning of fossil fuel by cars, trucks and buses, according to a warning issued today by Harvard researchers and the American Public Health Association (APHA).

29 Apr 2004

Household molds trigger allergic rhinitis

April showers can increase the amount of mold found inside and outside the home. Along with pollens from trees, grasses, and weeds, molds are an important trigger of allergic rhinitis, affecting nearly 40 million Americans, according to the American Academy of Allergy, Asthma & Immunology (AAAAI).

12 Apr 2004

Ban Chlorpyrifos and Diazinonon Impacts Child Birth Weights

A federal ban on two insecticides has resulted in a significant reduction in their impact on newborns' birth weight and length, according to a new study funded by the National Institute of Environmental Health Sciences of the National Institutes of Health, the U.S. Environmental Protection Agency, and other private foundations.

23 Mar 2004

Forward step in treatment of Allergic Rhinitis

Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company’s lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.

22 Mar 2004